Clinical trials: Systemic Juvenile Idiopathic Arthritis (sJIA)
Juvenile Idiopathic Arthritis
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)
This Phase IV, multicenter, single-arm, open-label study will evaluate the efficacy and safety of tocilizumab in Chinese participants with sJIA with persistent activity and an inadequate response to non-steroidal…
- Trial name
- NCT03301883
- Testing
- Tocilizumab, NSAIDs, CSs
- Where
- 10 sites in China
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Systemic Juvenile Idiopathic Arthritis With Active Flare
Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
This two-part study assessed the sustained efficacy of canakinumab in the double-blind Part II and the ability to taper steroids in the open label Part I.
- Trial name
- β-SPECIFIC 2 (NCT00889863)
- Testing
- canakinumab
- Where
- 73 sites in United States, Argentina and 17 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset
A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)
The aim of this study is to demonstrate the efficacy and to evaluate the safety, pharmacokinetics (PK) and immunogenicity of anakinra in patients with newly diagnosed Still's disease, including SJIA (Systemic juvenile idiopathic…
- Trial name
- anaSTILLs (NCT03265132)
- Testing
- anakinra
- Where
- 39 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Swedish Orphan Biovitrum
Systemic Juvenile Idiopathic Arthritis
Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
An open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with sJIA who were participated in Studies MRA011JP or MRA316JP
- Trial name
- NCT00144612
- Testing
- MRA(Tocilizumab)
- Volunteers
- 60 people
- Sponsor
- Chugai Pharmaceutical
Systemic-Onset Juvenile Idiopathic Arthritis
Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS
1. Main objective: To test the efficacy of anakinra treatment in children or young adults with corticosteroid-resistant or -dependent Systemic-Onset Juvenile Idiopathic Arthritis (SO-JIA) 2.
- Trial name
- NCT00339157
- Testing
- Anakinra, Pneumo23
- Where
- 6 sites in France
- Volunteers
- 24 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic
New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome
Macrophage activation syndrome(MAS) is a complication of bone marrow suppression, coagulopathy and CNS dysfunction which occurs in rheumatic diseases.
- Trial name
- MAS-D (NCT01095146)
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Amrita Institute of Medical Sciences & Research Center
Systemic Juvenile Idiopathic Arthritis (sJIA), Adult Onset Still's Disease (AOSD)
An Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD)
The purpose of this study is to evaluate the efficacy and safety of anakinra in Chinese patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD).The study consists of up to four weeks…
- Trial name
- NCT07706868
- Testing
- Anakinra (Kineret®)
- Sponsor
- Swedish Orphan Biovitrum
Juvenile Idiopathic Arthritis
A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)
This is a multi-center, open-label single-arm study to investigate the pharmacokinetics and safety of tocilizumab (RoActemra/Actemra) in participants less than 2 years old with active sJIA.
- Trial name
- NCT01455701
- Testing
- Tocilizumab
- Where
- 20 sites in United States, Argentina and 6 more
- Volunteers
- 11 people
- Sponsor
- Hoffmann-La Roche
Still Disease, Juvenile Onset
Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)
The purpose of the study is to evaluate and characterize long-term safety of Kineret when used in standard clinical practice to treat patients with systemic juvenile idiopathic arthritis (SJIA).
- Trial name
- NCT03932344
- Testing
- Anakinra
- Where
- Italy
- Volunteers
- 306 people
- Sponsor
- Swedish Orphan Biovitrum
Juvenile Idiopathic Arthritis
A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)
PART1 Participants in Part 1 (Run-in-Phase) of study will receive tocilizumab (TCZ) (RoActemra/Actemra) 12 milligrams per kilogram (mg/kg) or 8 mg/kg intravenously (IV) every 2 weeks (Q2W) for up to 24 weeks.
- Trial name
- NCT01734382
- Testing
- Tocilizumab
- Where
- 19 sites in United States, Argentina and 8 more
- Volunteers
- 35 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis
Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults
Systemic juvenile idiopathic arthritis (SJIA) is a type of arthritis that typically occurs before 16 years of age. SJIA usually involves heat, pain, swelling, and stiffness in the body's joints.
- Trial name
- NCT00534495
- Testing
- Rilonacept
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Montefiore Medical Center
Still´s Disease
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 (arumakimig) in pediatric and adult participants with Still's disease
- Trial name
- NCT07203001
- Testing
- MAS825
- Where
- 23 sites in United States, Canada and 6 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Familial Mediterranean Fever, Still Disease
A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including…
- Conditions
- Familial Mediterranean Fever, Still Disease, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still Disease
- Trial name
- NCT07517250
- Where
- Switzerland
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Active Systemic Juvenile Idiopathic Arthritis
To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.
A multicenter, randomized Phase II/III clinical study to evaluate the efficacy and safety of GenaKumab in the treatment of active systemic juvenile idiopathic arthritis.
- Trial name
- NCT05925452
- Testing
- GenaKumab
- Where
- 10 sites in China
- Volunteers
- 290 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant…
- Conditions
- Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias
- Trial name
- HSCT+RIC (NCT01962415)
- Testing
- Hydroxyurea, Alemtuzumab, Fludarabine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Paul Szabolcs
Systemic Juvenile Idiopathic Arthritis
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA).
- Trial name
- NCT04088396
- Testing
- Baricitinib, Tocilizumab
- Where
- 55 sites in Argentina, Belgium and 12 more
- Volunteers
- 58 people
- Sponsor
- Eli Lilly and Company
Systemic Juvenile Idiopathic Arthritis
Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
This is a double-blind, Phase III study to evaluate the efficacy, safety and PK of MRA in patients with sJIA.
- Trial name
- NCT00144599
- Testing
- MRA(Tocilizumab)
- Volunteers
- 56 people
- Sponsor
- Chugai Pharmaceutical
Juvenile Idiopathic Arthritis
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
This open-label, multicenter study will evaluate the pharmacokinetics, pharmacodynamics, and safety of subcutaneously administered tocilizumab in participants with Systemic Juvenile Idiopathic Arthritis (sJIA).
- Trial name
- NCT01904292
- Testing
- Tocilizumab
- Where
- 42 sites in United States, Argentina and 10 more
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis…
- Conditions
- Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus
- Trial name
- EMERALD (NCT05001737)
- Testing
- Emapalumab
- Where
- 44 sites in United States, Belgium and 11 more
- Volunteers
- 33 people
- Sponsor
- Swedish Orphan Biovitrum
Juvenile Rheumatoid Arthritis
Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis
The primary objective of this study was to determine the efficacy of etanercept in pediatric patients with systemically active system onset juvenile rheumatoid arthritis (SOJRA).
- Trial name
- NCT00078806
- Testing
- Etanercept
- Volunteers
- 19 people
- Sponsor
- Amgen